ArticleChinese medicine2025
Sanhuang Xiexin Decoction ameliorates lipid disorders in obese mice via inducing browning of white adipose tissue and activating brown adipose tissue.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ellagic Acid Prevents Obesity in High-Fat Diet-Fed Rats by Ameliorating Oxidative Stress via Modulation of the PPARG/STAT3/p-AKT1 Axis.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundObesity has become a critical public health challenge worldwide. Prioritizing prevention and tackling root causes-rather than merely managing symptoms-is critical to curbing this pandemic. Strategies that activate and expand brown adipose tissue and beige adipose tissue increase energy expenditure in animal models and offer therapeutic promise to treat obesity. Sanhuang Xiexin Decoction (SHX) is a well-known traditional Chinese medicine that possesses several beneficial effects, including anti-inflammatory and anti-atherosclerotic properties. This study aims to investigate whether SHX can alleviate obesity by promoting the browning process in adipose tissue.
methodsUPLC MS/MS was used to detect the constituents of SHX extraction, as well as the absorbed components of SHX in rat plasma. In vivo, C57BL/6 J mice were fed with 60% calorie high-fat diet for 8 weeks to induce obesity. 3T3-L1 white adipocyte and HIB-1B brown adipocyte were cultured. Parameters of body weight, food intake, Lee's index, skin temperature, adipose tissue mass, and blood glucose and lipids of mice were detected. The histological features of BAT and iWAT were observed by H&E staining, and the protein expression of UCP1 in adipose tissue was detected by immunohistochemistry method, and the UCP1 protein expression of 3T3-L1 and HIB-1B cells was tested using immunofluorescence staining. Gene expression of browning markers (e.g. Ucp1, Pgc1α, Prdm16, Cidea, Cd137, Tbx1, and Tmem26), fatty acid oxidation factors (e.g. Cpt-1β, Cyto-c, and Fatp1) and mitochondrial biogenic transcription factors (e.g. Nrf1, Nrf2, and Tfam) of adipose tissue, 3T3-L1 and HIB-1B cells was detected using qRT-PCR method.
resultsA total of 58 chemical components of Sanhuang Xiexin Decoction were identified by UPLC-LTQ-Orbitrap-MS
conclusionsOur study suggested that Sanhuang Xiexin Decoction could be used as a potential therapeutic candidate for the treatment of obesity and its complications by inducing browning of white adipose tissue and activating brown adipose tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.